Drug Trial Radar · NCT00872469
World Maternal Antifibrinolytic Trial
Last checked: Nov 19, 2026Latest source record: Feb 26, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
20,060
Actual
Start
May 2009
Primary completion
Jun 2016
Study completion Apr 2017
Sponsor
- Lead sponsor
- London School of Hygiene and Tropical MedicineAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Mar 31, 2009
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- Female only, from 16 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The WOMAN trial is a large pragmatic randomised double-blind, placebo controlled trial to quantify the effects of the early administration of tranexamic acid on death, hysterectomy and other relevant outcomes. 20,000 adult women, after delivery who have clinically diagnosed postpartum haemorrhage, are eligible if the responsible doctor is for any reason substantially uncertain whether or not to use an antifibrinolytic agent. Additionally, TWO nested studies will be conducted in a subset of women trial participants. The first nested study (ETAC) aims to evaluate the effect of tranexamic acid (TXA) on markers of coagulation in 400 women randomised to the WOMAN trial. The second nested study (ETAPLAT) aims to evaluate the haemostatic effect and antithrombotic effect of TXA in 128 women randomised to the WOMAN trial.
Conditions
- Postpartum Haemorrhage
Interventions
Tranexamic acidDrug
1-2 grams by intravenous injection
Placebo [Saline]Drug
Matched to active comparator
Primary outcomes
What the sponsor says the trial is designed to measure.
- The primary outcome is the proportion of women who die or undergo hysterectomy. The primary cause of death will be described.Time frame: up to 42 days after randomisation
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University College Hospital
Ibadan, Nigeria
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.